BioWorld & Medical Device Daily
Read More…BioVista Inc. has drugs in various stages of research and preclinical development for eye disorders, diabetes and obesity. According to its website, the Charlottesville, Va.-based company has identified four novel targets involved in diabetes and obesity that lend them- selves to the development of RNAi drugs.
Using artificial intelligence (AI), BioVista created a drug profiling plat- form that can identify new uses for existing compounds, providing the start-up with dozens of options for internal development as well as part- nerships and financing. The company…